When should MRSA coverage be discontinued?

When to Discontinue MRSA Coverage

Discontinue empirical MRSA antibiotics after 48 hours if cultures remain negative for MRSA or if cultures grow organisms other than MRSA, unless the patient has failed to respond clinically to beta-lactam therapy. 1

Clinical Decision Algorithm

For Skin and Soft Tissue Infections (SSTI)

Purulent Cellulitis/Abscesses:

• If cultures grow non-MRSA organisms → switch to targeted therapy immediately 1
• If cultures negative at 48-72 hours AND patient improving → discontinue MRSA coverage 1
• Total duration: 5-10 days based on clinical response 1

Non-purulent Cellulitis:

• Start with beta-lactam therapy (e.g., cefazolin) for streptococcal coverage 1
• Only add MRSA coverage if patient fails to respond to beta-lactam therapy 1
• If MRSA coverage was started empirically and cultures negative at 48 hours → discontinue MRSA antibiotics 1

For Critically Ill Patients

Respiratory Cultures:

• 85% of MRSA-positive respiratory cultures are positive by 48 hours
• 97% are positive by 72 hours 2
• If sputum cultures negative for MRSA at 48 hours → discontinue vancomycin (only 15% risk of subsequent MRSA growth) 2

Blood Cultures:

• 97.6% of MRSA bacteremia shows Gram-positive cocci on Gram stain within 48 hours 2
• If blood cultures show no Gram-positive cocci at 48 hours → discontinue MRSA coverage 2
• If Gram-positive cocci present but speciation pending → continue until final identification

For Complicated SSTI (Hospitalized Patients)

• Empirical MRSA coverage reasonable pending cultures 1
• Switch to beta-lactam (e.g., cefazolin) if cultures grow MSSA or streptococci 1
• If cultures negative at 48 hours AND clinical improvement → discontinue MRSA coverage 1
• Total duration: 7-14 days based on clinical response 1

Important Caveats

MRSA Carriage Status Should NOT Guide Treatment:

• Previous MRSA colonization has poor predictive value (sensitivity 68%, specificity 77%) 3
• 53% of current MRSA carriers and 43% of past carriers were successfully treated WITHOUT anti-MRSA antibiotics 3
• Do not reflexively continue MRSA coverage based solely on colonization history 3

Exception - Consider Continuing MRSA Coverage:

• Known MRSA carriers with septic arthritis (45.5% of MRSA arthritis occurred in known carriers) 4
• Patients with systemic toxicity who fail beta-lactam therapy 1
• Documented MRSA infection requiring completion of therapy course

Stewardship Considerations

The 48-hour rule is supported by antimicrobial stewardship data showing that antibiotic timeouts, rapid diagnostic testing, and MRSA nasal PCR screening effectively reduce unnecessary anti-MRSA use 5. Negative MRSA nasal PCR has high negative predictive value and can support early discontinuation decisions 5.

For hospitalized patients on empirical vancomycin, implementing a structured 48-hour culture review with discontinuation of MRSA coverage when cultures are negative or grow non-MRSA organisms represents evidence-based stewardship 2, 5.